This study is testing a new medicine called REGN7508 to see if it helps prevent strokes better than an existing medicine called apixaban. It is for adults with atrial fibrillation, a condition where the heart beats too fast and unevenly. Researchers want to know how safe and effective REGN7508 is in stopping strokes or clots in the body, and compare it to apixaban. They are also looking at possible side effects and if the body reacts to the new drug by making antibodies, which could make the drug less effective.
- Study Length: Detailed timeline not provided, but participation involves regular check-ups.
- Eligibility: Participants need to have atrial fibrillation and meet specific health criteria.
- Compensation/Risks: Not specified, but participants may experience side effects from the study drug.
How understandable was the trial content above?
Hard to understand
Easy to understand